270 related articles for article (PubMed ID: 28957419)
21. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.
Mudhasani R; Tran JP; Retterer C; Radoshitzky SR; Kota KP; Altamura LA; Smith JM; Packard BZ; Kuhn JH; Costantino J; Garrison AR; Schmaljohn CS; Huang IC; Farzan M; Bavari S
J Virol; 2013 Aug; 87(15):8451-64. PubMed ID: 23720721
[TBL] [Abstract][Full Text] [Related]
22. IFITM proteins inhibit HIV-1 protein synthesis.
Lee WJ; Fu RM; Liang C; Sloan RD
Sci Rep; 2018 Sep; 8(1):14551. PubMed ID: 30266929
[TBL] [Abstract][Full Text] [Related]
23. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity.
Gómez-Herranz M; Taylor J; Sloan RD
J Biol Chem; 2023 Jan; 299(1):102741. PubMed ID: 36435199
[TBL] [Abstract][Full Text] [Related]
24. The IFITMs Inhibit Zika Virus Replication.
Savidis G; Perreira JM; Portmann JM; Meraner P; Guo Z; Green S; Brass AL
Cell Rep; 2016 Jun; 15(11):2323-30. PubMed ID: 27268505
[TBL] [Abstract][Full Text] [Related]
25. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle.
Giguère JF; Bounou S; Paquette JS; Madrenas J; Tremblay MJ
J Virol; 2004 Jun; 78(12):6222-32. PubMed ID: 15163715
[TBL] [Abstract][Full Text] [Related]
26. Functional Involvement of Interferon-Inducible Transmembrane Proteins in Antiviral Immunity.
Liao Y; Goraya MU; Yuan X; Zhang B; Chiu SH; Chen JL
Front Microbiol; 2019; 10():1097. PubMed ID: 31156602
[TBL] [Abstract][Full Text] [Related]
27. Virion-targeted viral inactivation: new therapy against viral infection.
Okui N; Kitamura Y; Kobayashi N; Sakuma R; Ishikawa T; Kitamura T
Mol Urol; 2001; 5(2):59-66. PubMed ID: 11690549
[TBL] [Abstract][Full Text] [Related]
28. Induced Packaging of Cellular MicroRNAs into HIV-1 Virions Can Inhibit Infectivity.
Bogerd HP; Kennedy EM; Whisnant AW; Cullen BR
mBio; 2017 Jan; 8(1):. PubMed ID: 28096489
[TBL] [Abstract][Full Text] [Related]
29. Current Progress on Host Antiviral Factor IFITMs.
Ren L; Du S; Xu W; Li T; Wu S; Jin N; Li C
Front Immunol; 2020; 11():543444. PubMed ID: 33329509
[TBL] [Abstract][Full Text] [Related]
30. [Research Progress on Antiviral Activity of Interferon-induced Transmembrane Proteins].
Chen Y; Zhu W; Shu Y
Bing Du Xue Bao; 2016 Mar; 32(2):222-8. PubMed ID: 27396168
[TBL] [Abstract][Full Text] [Related]
31. Role of Viral Envelope Proteins in Determining Susceptibility of Viruses to IFITM Proteins.
Marceau T; Braibant M
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400030
[TBL] [Abstract][Full Text] [Related]
32. IFITM Genes, Variants, and Their Roles in the Control and Pathogenesis of Viral Infections.
Zhao X; Li J; Winkler CA; An P; Guo JT
Front Microbiol; 2018; 9():3228. PubMed ID: 30687247
[TBL] [Abstract][Full Text] [Related]
33. ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity.
Gurer C; Höglund A; Höglund S; Luban J
J Virol; 2005 May; 79(9):5557-67. PubMed ID: 15827170
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.
Aiken C
Virology; 1998 Aug; 248(1):139-47. PubMed ID: 9705263
[TBL] [Abstract][Full Text] [Related]
35. The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents.
Mathys L; Balzarini J
Retrovirology; 2014 Dec; 11():107. PubMed ID: 25499264
[TBL] [Abstract][Full Text] [Related]
36. IFITM3 directly engages and shuttles incoming virus particles to lysosomes.
Spence JS; He R; Hoffmann HH; Das T; Thinon E; Rice CM; Peng T; Chandran K; Hang HC
Nat Chem Biol; 2019 Mar; 15(3):259-268. PubMed ID: 30643282
[TBL] [Abstract][Full Text] [Related]
37. [The Research Advances in Antiviral Immune Molecules: Interferon Inducible Transmembrane Proteins].
Wang A; Chen S; Wang M; Cheng A
Bing Du Xue Bao; 2016 Jul; 32(4):509-15. PubMed ID: 29996041
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
39. Nef stimulates human immunodeficiency virus type 1 replication in primary T cells by enhancing virion-associated gp120 levels: coreceptor-dependent requirement for Nef in viral replication.
Lundquist CA; Zhou J; Aiken C
J Virol; 2004 Jun; 78(12):6287-96. PubMed ID: 15163722
[TBL] [Abstract][Full Text] [Related]
40. Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope.
Zhou J; Aiken C
J Virol; 2001 Jul; 75(13):5851-9. PubMed ID: 11390586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
